Core Viewpoint - Gelteq Limited is entering production of 400,000 units of its gel solution, aimed at fulfilling orders in the U.S. and Australia, with expected delivery in January 2025 [1][2] Company Overview - Gelteq Limited is a clinical and science-based company headquartered in Melbourne, Australia, focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products [3] - The company targets five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition [3] Production and Sales - The current production run includes Gelteq nutraceutical products in sports, anti-aging, and weight loss categories [1] - The production run is seen as a validation of Gelteq's gel-based technology and its ability to generate revenues in the near term [2] Partnerships and Growth - Gelteq has strengthened its partnership with Monash Innovation Labs to effectively scale operations and meet client needs while ensuring product quality [2] - The substantial orders related to the current production run are expected to lead to even larger volume orders in the future [2]
Gelteq Announces 400,000 Units Enter into Production in November 2024